What is the primary reason for this 8-K filing?

This 8-K filing is primarily to announce the retirement of Dominic J. Caruso, the Executive Vice President and Chief Financial Officer, and the subsequent appointment of Joseph Wolk as his successor.

Who is replacing Dominic Caruso as CFO?

Joseph Wolk, who has been serving as the Vice President of Investor Relations, has been appointed as the new Executive Vice President, Chief Financial Officer.

When will the leadership change at the CFO position take effect?

Joseph Wolk's appointment as CFO is effective July 1, 2018, while Dominic Caruso will remain in his role until his retirement in September 2018, allowing for a smooth transition.

What is Joseph Wolk's background within Johnson & Johnson?

Joseph Wolk has a comprehensive financial background within Johnson & Johnson since joining in 1998. His experience includes roles such as Vice President of Investor Relations, Vice President of Group Finance for the Pharmaceuticals Group, and various finance leadership positions within the Medical Devices and North America Pharmaceuticals groups.

JNJ 8-K: Leadership Changes

Summary

Johnson & Johnson (JNJ) announced a significant leadership transition, with Executive Vice President and Chief Financial Officer Dominic J. Caruso electing to retire in September 2018. This change marks the end of Mr. Caruso's tenure, during which he played a key role in the company's financial management. His departure necessitates a succession plan, ensuring continuity in financial oversight for the healthcare giant. To fill the CFO vacancy, the company has appointed Joseph Wolk, currently Vice President of Investor Relations, to the position of Executive Vice President, Chief Financial Officer, effective July 1, 2018. Mr. Wolk's extensive experience within JNJ's financial and operational divisions, including leadership roles in Pharmaceuticals and Medical Devices, positions him well for this critical executive role. His transition to CFO and membership on the Executive Committee signals a continued focus on financial strategy and stakeholder communication.

Key Highlights

1Dominic J. Caruso, EVP and CFO, to retire in September 2018.
2Joseph Wolk appointed as the new EVP and CFO, effective July 1, 2018.
3Mr. Wolk will report directly to Chairman and CEO Alex Gorsky.
4Mr. Wolk will become a member of the company's Executive Committee.
5Mr. Wolk has a strong background in JNJ's financial operations, including leadership in Investor Relations and Pharmaceutical Finance.
6The transition ensures continuity in financial leadership at the executive level.

JOHNSON & JOHNSON 8-K Report, Executive Changes (Mar 20, 2018)

Summary

Key Highlights

Frequently Asked Questions